Sanofi is one of several pharma companies that is on a quest to use digital health to make trials cheaper and more effective – and has found another partner to help it.
Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.